Jw Pharmac
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more
Jw Pharmac (001060) - Total Assets
Latest total assets as of September 2025: ₩611.56 Billion KRW
Based on the latest financial reports, Jw Pharmac (001060) holds total assets worth ₩611.56 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jw Pharmac - Total Assets Trend (2000–2024)
This chart illustrates how Jw Pharmac’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jw Pharmac - Asset Composition Analysis
Current Asset Composition (December 2024)
Jw Pharmac's total assets of ₩611.56 Billion consist of 50.7% current assets and 49.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.7% |
| Accounts Receivable | ₩135.50 Billion | 22.4% |
| Inventory | ₩111.73 Billion | 18.5% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩40.84 Billion | 6.8% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Jw Pharmac's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jw Pharmac's current assets represent 50.7% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 1.7% of total assets in 2024, down from 15.1% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 22.4% of total assets.
Jw Pharmac Competitors by Total Assets
Key competitors of Jw Pharmac based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Jw Pharmac - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Jw Pharmac generates 1.19x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Jw Pharmac generates $ 10.76 in net profit.
Jw Pharmac - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.51 | 1.42 | 1.28 |
| Quick Ratio | 0.98 | 0.96 | 0.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩111.85 Billion | ₩ 106.27 Billion | ₩ 64.58 Billion |
Jw Pharmac - Advanced Valuation Insights
This section examines the relationship between Jw Pharmac's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.30 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -6.3% |
| Total Assets | ₩604.60 Billion |
| Market Capitalization | $278.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jw Pharmac's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jw Pharmac's assets decreased by 6.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jw Pharmac (2000–2024)
The table below shows the annual total assets of Jw Pharmac from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩604.60 Billion | -6.27% |
| 2023-12-31 | ₩645.04 Billion | +2.72% |
| 2022-12-31 | ₩627.97 Billion | -0.80% |
| 2021-12-31 | ₩633.05 Billion | +15.29% |
| 2020-12-31 | ₩549.09 Billion | -4.21% |
| 2019-12-31 | ₩573.21 Billion | -3.47% |
| 2018-12-31 | ₩593.79 Billion | -5.88% |
| 2017-12-31 | ₩630.87 Billion | -3.10% |
| 2016-12-31 | ₩651.08 Billion | +6.13% |
| 2015-12-31 | ₩613.48 Billion | +3.26% |
| 2014-12-31 | ₩594.12 Billion | +0.81% |
| 2013-12-31 | ₩589.37 Billion | -2.28% |
| 2012-12-31 | ₩603.15 Billion | -9.59% |
| 2011-12-31 | ₩667.09 Billion | +29.32% |
| 2006-12-31 | ₩515.85 Billion | +7.92% |
| 2005-12-31 | ₩477.97 Billion | +4.46% |
| 2004-12-31 | ₩457.56 Billion | +11.06% |
| 2003-12-31 | ₩412.00 Billion | +6.85% |
| 2002-12-31 | ₩385.60 Billion | +0.08% |
| 2001-12-31 | ₩385.28 Billion | -3.06% |
| 2000-12-31 | ₩397.46 Billion | -- |